Exposure

Treatment exposure

Approximately one third of patients were able to stay on YONDELIS® 6 cycles or longer

1 out of 3 (34%) patients in the YONDELIS® group received 6 or more cycles of treatment, and 1 out of 10 (10%) received 12 or more cycles.1

Cumulative treatment cycles received (All treated patients)2
Treatment cycles received YONDELIS®
(n=340) % (n)
≥3 57.1 (194)
≥6 34.4 (117)
≥9 17.4 (59)
≥12 10.3 (35)
Treatment cycles received Dacarbazine
(n=155) % (n)
≥3 43.2 (67)
≥6 17.4 (27)
≥9 5.2 (8)
≥12 1.9 (3)

References:

  1. Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34(8):786-793.
  2. Demetri GD, von Mehren M, Jones RL, et al. Patient-reported outcomes from randomized, phase 3 study of trabectedin vs dacarbazine in advanced leiomyosarcoma or liposarcoma. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 3-7, 2016; Chicago, IL.